{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:24:41Z","timestamp":1784543081341,"version":"3.55.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100019345","name":"King Salman Center for Disability Research","doi-asserted-by":"publisher","award":["KSRG-2024-433"],"award-info":[{"award-number":["KSRG-2024-433"]}],"id":[{"id":"10.13039\/501100019345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-03829-4","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T08:49:48Z","timestamp":1749113388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A PBPK modeling approach for personalized dose optimization of nicardipine in renal and hepatic dysfunction"],"prefix":"10.1038","volume":"15","author":[{"given":"Ammara","family":"Ayub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammara","family":"Zamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Fawad","family":"Rasool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faleh","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"3829_CR1","first-page":"4611","volume":"55","author":"LT Baxter","year":"1995","unstructured":"Baxter, L. T., Zhu, H., Mackensen, D. G., Butler, W. F. & Jain, R. K. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based Pharmacokinetic model. Cancer Res. 55, 4611\u20134622 (1995).","journal-title":"Cancer Res."},{"key":"3829_CR2","first-page":"1517","volume":"54","author":"LT Baxter","year":"1994","unstructured":"Baxter, L. T., Zhu, H., Mackensen, D. G. & Jain, R. K. Physiologically based Pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 54, 1517\u20131528 (1994).","journal-title":"Cancer Res."},{"key":"3829_CR3","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1021\/nl803481q","volume":"9","author":"HA Lee","year":"2009","unstructured":"Lee, H. A., Leavens, T. L., Mason, S. E., Monteiro-Riviere, N. A. & Riviere, J. E. Comparison of quantum Dot biodistribution with a blood-flow-limited physiologically based Pharmacokinetic model. Nano Lett. 9, 794\u2013799 (2009).","journal-title":"Nano Lett."},{"key":"3829_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0378-4274(02)00374-0","volume":"138","author":"FP Theil","year":"2003","unstructured":"Theil, F. P., Guentert, T. W., Haddad, S. & Poulin, P. Utility of physiologically based Pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol. Lett. 138, 29\u201349 (2003).","journal-title":"Toxicol. Lett."},{"key":"3829_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-pharmtox-010510-100540","volume":"51","author":"M Rowland","year":"2011","unstructured":"Rowland, M., Peck, C. & Tucker, G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol. 51, 45\u201373 (2011).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"3829_CR6","first-page":"205","volume":"57","author":"T Teorell","year":"1937","unstructured":"Teorell, T. Kinetics of distribution of substances administered to the body, I: the extravascular modes of administration. Arch. Int. Pharmacodyn. Ther. 57, 205\u2013225 (1937).","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"3829_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.yrtph.2007.10.012","volume":"50","author":"RA Clewell","year":"2008","unstructured":"Clewell, R. A. & Clewell, I. I. I. Development and specification of physiologically based Pharmacokinetic models for use in risk assessment. Regul. Toxicol. Pharmacol. 50, 129\u2013143 (2008).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"3829_CR8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10928-016-9492-y","volume":"43","author":"C Hartmanshenn","year":"2016","unstructured":"Hartmanshenn, C., Scherholz, M. & Androulakis, I. P. Physiologically-based Pharmacokinetic models: approaches for enabling personalized medicine. J. Pharmacokinet. Pharmacodyn. 43, 481\u2013504 (2016).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"3829_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2165\/00003088-200847040-00004","volume":"47","author":"SA Peters","year":"2008","unstructured":"Peters, S. A. Evaluation of a generic physiologically based Pharmacokinetic model for lineshape analysis. Clin. Pharmacokinet. 47, 261\u2013275 (2008).","journal-title":"Clin. Pharmacokinet."},{"key":"3829_CR10","doi-asserted-by":"publisher","first-page":"8589","DOI":"10.1038\/s41598-021-88154-2","volume":"11","author":"MF Rasool","year":"2021","unstructured":"Rasool, M. F. et al. Development and evaluation of physiologically based Pharmacokinetic drug-disease models for predicting Captopril Pharmacokinetics in chronic diseases. Sci. Rep. 11, 8589 (2021).","journal-title":"Sci. Rep."},{"key":"3829_CR11","doi-asserted-by":"publisher","first-page":"29302","DOI":"10.1021\/acsomega.3c02673","volume":"8","author":"A Zamir","year":"2023","unstructured":"Zamir, A. et al. Physiologically based Pharmacokinetic model to predict Metoprolol disposition in healthy and disease populations. ACS Omega. 8, 29302\u201329313 (2023).","journal-title":"ACS Omega"},{"key":"3829_CR12","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11095-024-03664-8","volume":"41","author":"J Adiwidjaja","year":"2024","unstructured":"Adiwidjaja, J., Spires, J. & Brouwer, K. L. Physiologically based Pharmacokinetic (PBPK) model predictions of disease mediated changes in drug disposition in patients with nonalcoholic fatty liver disease (NAFLD). Pharm. Res. 41, 441\u2013462 (2024).","journal-title":"Pharm. Res."},{"key":"3829_CR13","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.xphs.2021.02.001","volume":"110","author":"J Zhou","year":"2021","unstructured":"Zhou, J. et al. Dosage adjustment for Ceftazidime in pediatric patients with renal impairment using physiologically based Pharmacokinetic modeling. J. Pharm. Sci. 110, 1853\u20131862 (2021).","journal-title":"J. Pharm. Sci."},{"key":"3829_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s13318-016-0353-2","volume":"42","author":"MF Rasool","year":"2017","unstructured":"Rasool, M. F., Khalil, F. & L\u00e4er, S. Optimizing the clinical use of carvedilol in liver cirrhosis using a physiologically based Pharmacokinetic modeling approach. Eur. J. Drug Metab. Pharmacokinet. 42, 383\u2013396 (2017).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"3829_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/ph17070924","volume":"17","author":"M Pasha","year":"2024","unstructured":"Pasha, M. et al. A comprehensive physiologically based Pharmacokinetic model for predicting vildagliptin pharmacokinetics: insights into dosing in renal impairment. Pharmaceuticals 17, 924 (2024).","journal-title":"Pharmaceuticals"},{"key":"3829_CR16","doi-asserted-by":"publisher","first-page":"e5425","DOI":"10.1002\/bmc.5425","volume":"36","author":"YH Jung","year":"2022","unstructured":"Jung, Y. H. et al. Effect of concomitant oral administration of ethanol on the pharmacokinetics of Nicardipine in rats. Biomed. Chromatogr. 36, e5425 (2022).","journal-title":"Biomed. Chromatogr."},{"key":"3829_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/0165-6147(87)90103-9","volume":"8","author":"F Hofmann","year":"1987","unstructured":"Hofmann, F., Nastainczyk, W., R\u00f6hrkasten, A., Schneider, T. & Sieber, M. Regulation of the L-type calcium channel. Trends Pharmacol. Sci. 8, 393\u2013398 (1987).","journal-title":"Trends Pharmacol. Sci."},{"key":"3829_CR18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/00005344-199015004-00002","volume":"15","author":"H Struyker-Boudier","year":"1990","unstructured":"Struyker-Boudier, H., Smits, J. & De Mey, J. The Pharmacology of calcium antagonists: a review. J. Cardiovasc. Pharmacol. 15, S1\u2013S10 (1990).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"3829_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1085\/jgp.86.1.1","volume":"86","author":"BP Bean","year":"1985","unstructured":"Bean, B. P. Two kinds of calcium channels in canine atrial cells. Differences in kinetics, selectivity, and Pharmacology. J. Gen. Physiol. 86, 1\u201330 (1985).","journal-title":"J. Gen. Physiol."},{"key":"3829_CR20","first-page":"123","volume":"5","author":"Y Krishnaiah","year":"2002","unstructured":"Krishnaiah, Y., Satyanarayana, V. & Karthikeyan, R. Effect of the solvent system on the in vitro permeability of Nicardipine hydrochloride through excised rat epidermis. J. Pharm. Pharm. Sci. 5, 123\u2013130 (2002).","journal-title":"J. Pharm. Pharm. Sci."},{"key":"3829_CR21","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1080\/17425255.2024.2402481","volume":"20","author":"A Ayub","year":"2024","unstructured":"Ayub, A. et al. Clinical pharmacokinetics and pharmacodynamics of Nicardipine; a systematic review. Expert Opin. Drug Metab. Toxicol. 20, 1053\u20131067 (2024).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"3829_CR22","doi-asserted-by":"publisher","first-page":"e7186","DOI":"10.1002\/ccr3.7186","volume":"11","author":"G Timour","year":"2023","unstructured":"Timour, G., Fr\u00e9deric, V., Olivier, S. & Shango, D. N. Nicardipine-induced acute respiratory failure: case report and literature review. Clin. Case Rep. 11, e7186 (2023).","journal-title":"Clin. Case Rep."},{"key":"3829_CR23","first-page":"226","volume":"18","author":"C Jun-Shik","year":"2010","unstructured":"Jun-Shik, C., Sung-Il, H. & Dong-Hyun, C. Effects of Atorvastatin on the pharmacokinetics of Nicardipine after oral and intravenous administration in rats. Korean Soc. Appl. Pharmacol. 18, 226\u2013232 (2010).","journal-title":"Korean Soc. Appl. Pharmacol."},{"key":"3829_CR24","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1248\/bpb.28.882","volume":"28","author":"K Nakamura","year":"2005","unstructured":"Nakamura, K. et al. Inhibitory effects of Nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol. Pharm. Bull. 28, 882\u2013885 (2005).","journal-title":"Biol. Pharm. Bull."},{"key":"3829_CR25","doi-asserted-by":"publisher","first-page":"195S","DOI":"10.1111\/j.1365-2125.1986.tb00322.x","volume":"22","author":"R Dow","year":"1986","unstructured":"Dow, R. & Graham, D. A review of the human metabolism and pharmacokinetics of Nicardipine hydrochloride. Br. J. Clin. Pharmacol. 22, 195S (1986).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"3829_CR26","doi-asserted-by":"publisher","first-page":"10S","DOI":"10.1177\/0091270011413588","volume":"52","author":"J Naud","year":"2012","unstructured":"Naud, J., Nolin, T. D., Leblond, F. A. & Pichette, V. Current Understanding of drug disposition in kidney disease. J. Clin. Pharmacol. 52, 10S\u201322S (2012).","journal-title":"J. Clin. Pharmacol."},{"key":"3829_CR27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1472-8206.1993.tb00257.x","volume":"7","author":"M Drici","year":"1993","unstructured":"Drici, M. et al. Clinical Pharmacology of Nicardipine in liver transplant patients. Fundam. Clin. Pharmacol. 7, 531\u2013536 (1993).","journal-title":"Fundam. Clin. Pharmacol."},{"key":"3829_CR28","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2165\/00003088-200847110-00005","volume":"47","author":"AN Edginton","year":"2008","unstructured":"Edginton, A. N. & Willmann, S. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin. Pharmacokinet. 47, 743\u2013752 (2008).","journal-title":"Clin. Pharmacokinet."},{"key":"3829_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2165\/11318160-000000000-00000","volume":"49","author":"TN Johnson","year":"2010","unstructured":"Johnson, T. N., Boussery, K., Rowland-Yeo, K., Tucker, G. T. & Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin. Pharmacokinet. 49, 189\u2013206 (2010).","journal-title":"Clin. Pharmacokinet."},{"key":"3829_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1586\/ecp.10.143","volume":"4","author":"K Rowland Yeo","year":"2011","unstructured":"Rowland Yeo, K., Aarabi, M., Jamei, M. & Rostami-Hodjegan, A. Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev. Clin. Pharmacol. 4, 261\u2013274 (2011).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"3829_CR31","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1002\/jcph.1713","volume":"60","author":"PR Malik","year":"2020","unstructured":"Malik, P. R. et al. A physiological approach to pharmacokinetics in chronic kidney disease. J. Clin. Pharmacol. 60, S52\u2013S62 (2020).","journal-title":"J. Clin. Pharmacol."},{"key":"3829_CR32","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/pharmaceutics16020280","volume":"16","author":"JM Lee","year":"2024","unstructured":"Lee, J. M., Yoon, J. H., Maeng, H. J. & Kim, Y. C. Physiologically based Pharmacokinetic (PBPK) modeling to predict CYP3A-mediated drug interaction between saxagliptin and Nicardipine: bridging rat-to-human extrapolation. Pharmaceutics 16, 280 (2024).","journal-title":"Pharmaceutics"},{"key":"3829_CR33","doi-asserted-by":"publisher","first-page":"55S","DOI":"10.1111\/j.1365-2125.1985.tb05143.x","volume":"20","author":"B Campbell","year":"1985","unstructured":"Campbell, B., Kelman, A. & Hillis, W. Noninvasive assessment of the haemodynamic effects of Nicardipine in normotensive subjects. Br. J. Clin. Pharmacol. 20, 55S\u201361S (1985).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"3829_CR34","doi-asserted-by":"publisher","first-page":"23S","DOI":"10.1111\/j.1365-2125.1985.tb05141.x","volume":"20","author":"D Graham","year":"1985","unstructured":"Graham, D. et al. The metabolism and pharmacokinetics of Nicardipine hydrochloride in man. Br. J. Clin. Pharmacol. 20, 23S\u201328S (1985).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"3829_CR35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/bdd.2510080205","volume":"8","author":"JG Wagner","year":"1987","unstructured":"Wagner, J. G. et al. Single intravenous dose and steady-state oral dose pharmacokinetics of Nicardipine in healthy subjects. Biopharm. Drug Dispos. 8, 133\u2013148 (1987).","journal-title":"Biopharm. Drug Dispos."},{"key":"3829_CR36","doi-asserted-by":"crossref","unstructured":"Hirota, N., Yonemaru, H., Yoshikawa, M., Naruto, H. Pharmacokinetics of Nicardipine following intravenous and oral administration to the same human subject. Drug Metab. Pharmacokinet. 13, 376\u2013381 (1998).","DOI":"10.2133\/dmpk.13.376"},{"key":"3829_CR37","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/BF02026502","volume":"4","author":"P Rocha","year":"1990","unstructured":"Rocha, P., Guerret, M., David, D., Marchand, X. & Kahn, J. Kinetics and hemodynamic effects of intravenous Nicardipine modified by previous propranolol oral treatment. Cardiovasc. Drugs Ther. 4, 1525\u20131532 (1990).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"3829_CR38","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/jps.2600820707","volume":"82","author":"NB Modi","year":"1993","unstructured":"Modi, N. B., Veng-Pedersen, P., Graham, D. J. & Dow, R. J. Application of a system analysis approach to population pharmacokinetics and pharmacodynamics of Nicardipine hydrochloride in healthy males. J. Pharm. Sci. 82, 705\u2013713 (1993).","journal-title":"J. Pharm. Sci."},{"key":"3829_CR39","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/clpt.1990.58","volume":"47","author":"T Razak","year":"1990","unstructured":"Razak, T. et al. The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to Nicardipine. Clin. Pharmacol. Ther. 47, 463\u2013469 (1990).","journal-title":"Clin. Pharmacol. Ther."},{"key":"3829_CR40","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/0021-9673(94)80142-8","volume":"668","author":"M Rosseel","year":"1994","unstructured":"Rosseel, M. & Lefebvre, R. Capillary gas chromatographic determination with nitrogen\u2014phosphorus detection of the calcium antagonist Nicardipine and its pyridine metabolite M-5 in plasma. J. Chromatogr. A. 668, 475\u2013480 (1994).","journal-title":"J. Chromatogr. A"},{"key":"3829_CR41","doi-asserted-by":"publisher","first-page":"297S","DOI":"10.1111\/j.1365-2125.1986.tb00335.x","volume":"22","author":"SM Lee","year":"1986","unstructured":"Lee, S. M., Williams, R., Warnock, D., Emmett, M. & Wolbach, R. A. The effects of Nicardipine in hypertensive subjects with impaired renal function. Br. J. Clin. Pharmacol. 22, 297S (1986).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"3829_CR42","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2133\/dmpk.24.389","volume":"24","author":"N Yamane","year":"2009","unstructured":"Yamane, N. et al. Microdose clinical trial: quantitative determination of Nicardipine and prediction of metabolites in human plasma. Drug Metab. Pharmacokinet. 24, 389\u2013403 (2009).","journal-title":"Drug Metab. Pharmacokinet."},{"key":"3829_CR43","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1478-5382(03)02342-4","volume":"1","author":"S Willmann","year":"2003","unstructured":"Willmann, S. et al. PK-Sim\u00ae: a physiologically based Pharmacokinetic \u2018whole-body\u2019model. Biosilico 1, 121\u2013124 (2003).","journal-title":"Biosilico"},{"key":"3829_CR44","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1080\/10641960802580190","volume":"30","author":"F Amenta","year":"2008","unstructured":"Amenta, F., Tomassoni, D., Traini, E., Mignini, F. & Veglio, F. Nicardipine: a hypotensive dihydropyridine-type calcium antagonist with a peculiar cerebrovascular profile. Clin. Exp. Hypertens. 30, 808\u2013826 (2008).","journal-title":"Clin. Exp. Hypertens."},{"key":"3829_CR45","unstructured":"Budavari, S. The Merck index, Merck research laboratories, Merck and Co. Inc Whitehouse Stn. NJ, 7401 (1996)."},{"key":"3829_CR46","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/00005344-198509000-00012","volume":"7","author":"S Urien","year":"1985","unstructured":"Urien, S., Albengres, E., Comte, A., Kiechel, J. R. & Tillement, J. P. Plasma protein binding and erythrocyte partitioning of Nicardipine in vitro. J. Cardiovasc. Pharmacol. 7, 891\u2013898 (1985).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"3829_CR47","unstructured":"PubChem Compound Summary for CID 4474, Nicardipine. National Center for Biotechnology Information (2024). (2024)."},{"key":"3829_CR48","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1177\/1087057107308892","volume":"12","author":"C Li","year":"2007","unstructured":"Li, C., Liu, T., Cui, X., Uss, A. S. & Cheng, K. C. Development of in vitro Pharmacokinetic screens using Caco-2, human hepatocyte, and Caco-2\/human hepatocyte hybrid systems for the prediction of oral bioavailability in humans. J. BioMol. Screen. 12, 1084\u20131091 (2007).","journal-title":"J. BioMol. Screen."},{"key":"3829_CR49","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1124\/dmd.119.087973","volume":"47","author":"K Holt","year":"2019","unstructured":"Holt, K., Ye, M., Nagar, S. & Korzekwa, K. Prediction of tissue-plasma partition coefficients using microsomal partitioning: incorporation into physiologically based Pharmacokinetic models and steady-state volume of distribution predictions. Drug Metab. Dispos. 47, 1050\u20131060 (2019).","journal-title":"Drug Metab. Dispos."},{"key":"3829_CR50","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.1002\/jps.22635","volume":"100","author":"K Beaumont","year":"2011","unstructured":"Beaumont, K., Gardner, I., Chapman, K., Hall, M. & Rowland, M. Toward an integrated human clearance prediction strategy that minimizes animal use. J. Pharm. Sci. 100, 4518\u20134535 (2011).","journal-title":"J. Pharm. Sci."},{"key":"3829_CR51","doi-asserted-by":"publisher","first-page":"11751","DOI":"10.3390\/ijms231911751","volume":"23","author":"EM Newman","year":"2022","unstructured":"Newman, E. M. & Rowland, A. A physiologically based Pharmacokinetic model to predict the impact of metabolic changes associated with metabolic associated fatty liver disease on drug exposure. Int. J. Mol. Sci. 23, 11751 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"3829_CR52","doi-asserted-by":"crossref","unstructured":"Kalam, M. N. et al. Development and evaluation of a physiologically based Pharmacokinetic drug-disease model of propranolol for suggesting model informed dosing in liver cirrhosis patients. Drug Des. Dev. Therapy, 1195\u20131211 (2021).","DOI":"10.2147\/DDDT.S297981"},{"key":"3829_CR53","unstructured":"Jing, J. Pharmacokinetics and Physiologically Based Pharmacokinetic Modeling of Xenobiotic Disposition in Special Populations, (2017)."},{"key":"3829_CR54","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2174\/1570163815666180807141922","volume":"16","author":"N George","year":"2019","unstructured":"George, N. et al. Chemistry and Pharmacological activities of Biginelli product-A brief overview. Curr. Drug Discov. Technol. 16, 127\u2013134 (2019).","journal-title":"Curr. Drug Discov. Technol."},{"key":"3829_CR55","doi-asserted-by":"crossref","unstructured":"Silva, C. F., Nascimento, C. S. Jr & Borges, K. Restricted dual access polypyrrole as an adsorbent in Pipette-Tip Solid-Phase extraction for simultaneous determination of nimodipine and Nicardipine from breast milk. Available SSRN 4236450 (2022).","DOI":"10.2139\/ssrn.4236450"},{"key":"3829_CR56","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster, A. C., Nagler, E. V., Morton, R. L. & Masson, P. Chronic kidney disease. Lancet 389, 1238\u20131252 (2017).","journal-title":"Lancet"},{"key":"3829_CR57","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","volume":"371","author":"D Schuppan","year":"2008","unstructured":"Schuppan, D. & Afdhal, N. H. Liver cirrhosis. Lancet 371, 838\u2013851 (2008).","journal-title":"Lancet"},{"key":"3829_CR58","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2165\/00003088-199937050-00004","volume":"37","author":"V Rodighiero","year":"1999","unstructured":"Rodighiero, V. Effects of liver disease on pharmacokinetics: an update. Clin. Pharmacokinet. 37, 399\u2013431 (1999).","journal-title":"Clin. Pharmacokinet."},{"key":"3829_CR59","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand, M., Hooker, A. C., Wallin, J. E. & Karlsson, M. O. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13, 143\u2013151 (2011).","journal-title":"AAPS J."},{"key":"3829_CR60","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","volume":"99","author":"Y Zhang","year":"2010","unstructured":"Zhang, Y., Huo, M., Zhou, J., Xie, S. & PKSolver An add-in program for Pharmacokinetic and pharmacodynamic data analysis in Microsoft excel. Comput. Methods Programs Biomed. 99, 306\u2013314 (2010).","journal-title":"Comput. Methods Programs Biomed."},{"key":"3829_CR61","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1002\/jcph.1741","volume":"60","author":"Y Franchetti","year":"2020","unstructured":"Franchetti, Y. & Nolin, T. D. Dose optimization in kidney disease: opportunities for PBPK modeling and simulation. J. Clin. Pharmacol. 60, S36\u2013S51 (2020).","journal-title":"J. Clin. Pharmacol."},{"key":"3829_CR62","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1081\/CEH-120034141","volume":"26","author":"F Mignini","year":"2004","unstructured":"Mignini, F. et al. Bioequivalence study of Nicardipine solution versus Nicardipine tablets. Clin. Exp. Hypertens. 26, 375\u2013386 (2004).","journal-title":"Clin. Exp. Hypertens."},{"key":"3829_CR63","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cpt.2125","volume":"110","author":"T Heimbach","year":"2021","unstructured":"Heimbach, T. et al. Physiologically-based Pharmacokinetic modeling in renal and hepatic impairment populations: a pharmaceutical industry perspective. Clin. Pharmacol. Ther. 110, 297\u2013310 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"3829_CR64","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/jcph.1784","volume":"61","author":"S Willmann","year":"2021","unstructured":"Willmann, S. et al. Applications of physiologically based Pharmacokinetic modeling of rivaroxaban\u2014Renal and hepatic impairment and drug-drug interaction potential. J. Clin. Pharmacol. 61, 656\u2013665 (2021).","journal-title":"J. Clin. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03829-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03829-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03829-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T10:03:20Z","timestamp":1749117800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03829-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3829"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03829-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19752"}}